CompletedNCT01105481
Amisulpride or placebo added to clozapine for resistant schizophrenia
About this title
Read the official source — NCT01105481Medication studyAges 18–60Taiwan
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Taipei County and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMay 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 273
- Sponsor
- National Health Research Institutes, Taiwan
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Taiwan
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT01105481
- Official title
Show the full official title
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients: A 14-week Randomized, Double-blind and Placebo-controlled Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedTaipei County · Taoyuan
Questions about this study
Who is behind this study?
The study sponsor is National Health Research Institutes, Taiwan.
Did this study involve medication?
Yes. The study involved medication, including Amisulpride add-on and Placebo add-on.
Who was this study for?
Listed age limits: 18 years to 60 years.
